How Much Retatrutide Per Week - Guide | Cured Pharmacy

How Much Retatrutide Per Week

HEALTH · 17 MIN READ
Written by Cured Pharmacy
Published on 24 June 2026

Retatrutide is generating significant interest across the UK as one of the most promising next-generation weight loss medications to emerge from clinical research, and if you have been researching it, you have almost certainly found yourself asking how much retatrutide per week is the correct dose, how dosing progresses over time, and what you can realistically expect in terms of results. With Phase 3 trials ongoing in 2026 and growing patient curiosity, understanding the science behind weekly dosing has never been more important for anyone considering this medication.

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 25 June 2026

Quick Summary

Retatrutide is a triple incretin receptor agonist being studied as a once-weekly injectable treatment for obesity. Clinical trial data reveals a carefully structured dose escalation plan that begins at 2 mg per week and may rise to 12 mg per week, with average weight loss outcomes exceeding those of any currently approved medication.

  • Retatrutide is administered once weekly via subcutaneous injection
  • Starting dose in Phase 2 trials was 2 mg per week, escalating over several months
  • The highest studied maintenance dose is 12 mg per week
  • Participants on 12 mg lost an average of 24.2% of body weight over 48 weeks
  • Retatrutide is not yet approved by the MHRA and remains under clinical investigation

Weekly Dose Titration Estimator

Select your current week of treatment to see what dose phase you may be in, based on the Phase 2 trial titration schedule used in clinical research.

This tool is for informational purposes only and is based on Phase 2 clinical trial data. Always follow guidance from your prescriber.

Table of Contents

  1. What Is Retatrutide and How Does It Work?
  2. How Much Retatrutide Per Week: The Clinical Dosing Schedule
  3. Understanding the Retatrutide Titration Schedule
  4. Retatrutide Weight Loss Results by Dose
  5. Managing Side Effects at Each Dose Level
  6. How Retatrutide Compares to Other Weekly Injectables
  7. Key Takeaways
  8. When to Seek Professional Advice
  9. Scientific References
  10. FAQs

What Is Retatrutide and How Does It Work?

Retatrutide, developed by Eli Lilly, is a first-in-class triple incretin receptor agonist. Unlike existing medications that act on one or two hormone receptors, retatrutide simultaneously targets three: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action sets it apart from currently approved options such as semaglutide and tirzepatide, giving it the potential to produce even greater metabolic effects on appetite, energy expenditure, and fat metabolism.

By activating the glucagon receptor in addition to GLP-1 and GIP, retatrutide increases energy expenditure more substantially than its predecessors. The glucagon pathway promotes the burning of stored fat and thermogenesis, meaning the body becomes more efficient at using fat as fuel. This makes retatrutide particularly appealing for individuals who have struggled to achieve meaningful results with existing weight loss treatments or lifestyle interventions alone.

The medication is administered as a once-weekly subcutaneous injection, typically into the abdomen, upper thigh, or upper arm. Its long half-life means once-weekly dosing maintains stable blood levels, which is ideal both for efficacy and patient adherence. Understanding how much retatrutide per week is appropriate requires first appreciating this pharmacological complexity and why dosing must be introduced gradually.

  • Triple incretin agonist: targets GLP-1, GIP, and glucagon receptors simultaneously
  • Subcutaneous injection administered once weekly
  • Promotes appetite reduction, improved insulin sensitivity, and fat burning
  • Currently in Phase 3 clinical trials as of 2026
  • Not yet approved by the MHRA for clinical use in the UK

How Much Retatrutide Per Week: The Clinical Dosing Schedule

The question of how much retatrutide per week is appropriate can only be fully answered by examining the carefully designed titration protocol used in Eli Lilly's Phase 2 trials, which were published in the New England Journal of Medicine in 2023. Participants were allocated to different dose cohorts: 1 mg, 2 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose arm represented the highest studied dose and produced the most dramatic results, with participants losing an average of 24.2% of their body weight over 48 weeks.

To reach the maintenance dose of 12 mg, participants did not begin at that level. Instead, every cohort followed a structured escalation pathway. Those assigned to the 12 mg arm began at 2 mg weekly for the first four weeks, then progressed through 4 mg and 8 mg at intervals, ultimately reaching 12 mg by approximately week 16 to 24. This slow escalation is medically necessary to reduce the likelihood of nausea, vomiting, and other gastrointestinal adverse effects that are common with incretin-based therapies when doses are increased too rapidly.

It is important to note that these doses were used in a controlled clinical trial setting and are not yet prescribed doses available via the NHS or licensed UK pharmacies. The dosing figures discussed throughout this article reflect trial protocols, not prescribing guidelines, which will only be established following full regulatory review.

  • Phase 2 trial doses ranged from 1 mg to 12 mg once weekly
  • The 12 mg weekly arm produced the greatest average weight loss
  • All participants began at lower doses and escalated gradually
  • Doses are not yet MHRA-licensed and cannot currently be prescribed in the UK
  • Ongoing Phase 3 trials will determine the final approved dosing regimen

Understanding the Retatrutide Titration Schedule

The titration schedule for retatrutide is one of the most clinically significant aspects of its use. Titration refers to the process of starting at a low dose and increasing it incrementally over weeks or months until the target maintenance dose is reached. This approach is standard practice across all GLP-1 class medications because the gastrointestinal tract needs time to adapt to the hormonal signalling changes caused by these agents.

Based on Phase 2 data, the general titration pathway for those targeting the 12 mg maintenance dose appears to proceed as follows. Weeks one through four involved 2 mg once weekly. This was then increased to 4 mg from weeks five through eight. A further escalation to 8 mg followed from approximately week nine, with the final increase to 12 mg occurring at around weeks 16 to 24 depending on individual tolerability. The retatrutide mg per week journey is therefore a months-long process rather than an immediate high-dose intervention.

For patients who experienced side effects at a particular dose, the protocol in trials allowed for the dose to be held at the current level until tolerability improved before proceeding to the next escalation step. This flexibility is a key feature of responsible clinical use and reflects how any eventual prescribing guidelines are likely to be structured once the medication receives regulatory approval. If you are managing obesity and exploring current approved options, our weight loss treatment range includes clinically reviewed medications available today.

Treatment Week Dose Phase Weekly Dose (mg) Primary Goal
Weeks 1–4 Initiation 2 mg Acclimatisation; minimise GI side effects
Weeks 5–8 Titration Phase 1 4 mg Begin meaningful appetite suppression
Weeks 9–16 Titration Phase 2 8 mg Significant metabolic effects and weight reduction
Weeks 17–24 Titration Phase 3 10–12 mg Approach maximum dose if well tolerated
Weeks 25–48+ Maintenance 12 mg Sustain weight loss at peak therapeutic dose
  • Titration typically spans 16 to 24 weeks before reaching the 12 mg maintenance dose
  • Each dose increment is held for a minimum of four weeks
  • Tolerability determines whether escalation proceeds on schedule
  • Dose holds are permitted without affecting long-term outcomes significantly

Retatrutide Weight Loss Results by Dose

One of the most compelling aspects of the Phase 2 retatrutide data is the clear dose-response relationship. Higher weekly doses were associated with greater average percentage body weight loss, providing a strong rationale for the slow titration to the highest tolerated maintenance dose. The results from the 48-week Phase 2 trial demonstrated outcomes that exceeded those seen with any previously approved anti-obesity medication.

Participants receiving 4 mg per week lost an average of approximately 8.7% of body weight. Those on 8 mg weekly achieved an average loss of around 17.3%, while the 12 mg group reached 24.2%. For context, semaglutide 2.4 mg weekly (Wegovy) produces approximately 15% average weight loss, and tirzepatide at its highest dose achieves around 20%. Retatrutide at 12 mg therefore represents a step change in what pharmacological intervention can achieve for obesity management.

It is worth noting that these figures represent averages across trial populations. Individual responses varied, and some participants achieved substantially greater weight loss while others responded more modestly. Factors including baseline body weight, metabolic health, dietary habits, and physical activity all influence outcomes. The retatrutide weekly injection dose you receive in a clinical setting would similarly be tailored to your individual circumstances rather than being a one-size-fits-all prescription.

  • 4 mg weekly: approximately 8.7% average body weight loss at 48 weeks
  • 8 mg weekly: approximately 17.3% average body weight loss at 48 weeks
  • 12 mg weekly: approximately 24.2% average body weight loss at 48 weeks
  • Results exceed those of semaglutide and tirzepatide in comparative context
  • Individual responses vary based on multiple metabolic and lifestyle factors

Managing Side Effects at Each Dose Level

Understanding the side effect profile at each weekly dose level is essential for anyone researching retatrutide. As with all GLP-1 receptor agonists and incretin-based therapies, the most commonly reported adverse effects in the Phase 2 trial were gastrointestinal in nature. These included nausea, vomiting, diarrhoea, constipation, and decreased appetite. The incidence and severity of these effects were closely linked to the rate of dose escalation and the absolute dose level.

At the 2 mg starting dose, side effects were generally mild and transient. The majority of participants tolerated this initiation phase well, with nausea being the most commonly reported symptom. As doses increased through the titration schedule, the proportion of participants experiencing nausea also increased, peaking in the 8 mg and 12 mg groups. However, in most cases these side effects were manageable and resolved over time as the body adapted. Serious adverse events were uncommon, and the overall safety profile was broadly consistent with that of other GLP-1 class agents.

Practical strategies for managing side effects at higher dose levels include eating smaller, lower-fat meals, avoiding strong food smells that trigger nausea, staying well hydrated, and taking the injection on a consistent day each week to maintain steady drug levels. If side effects become severe at a particular dose, the retatrutide titration schedule allows for a dose hold rather than discontinuation, meaning tolerability issues can be addressed without abandoning treatment entirely. Individuals with complex health backgrounds exploring medically supervised weight management should always discuss side effect management with their prescriber.

  • Nausea is the most common side effect, particularly during dose escalation phases
  • Vomiting, diarrhoea, and decreased appetite were also frequently reported
  • Side effects typically peaked early and diminished over weeks at each dose level
  • Dose holds rather than discontinuation are recommended for tolerability issues
  • Dietary adjustments significantly reduce the impact of GI side effects

How Retatrutide Compares to Other Weekly Injectables

Placing retatrutide in context alongside currently available weekly injectables helps to illustrate why there is such widespread anticipation around its eventual approval. The GLP-1 receptor agonist class has already transformed obesity treatment in recent years, with medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) offering unprecedented weight loss outcomes. Retatrutide, however, sits in a category of its own due to its additional glucagon receptor activity.

Semaglutide 2.4 mg weekly operates as a single GLP-1 agonist and produces an average weight loss of around 15% over 68 weeks in the STEP trial programme. Tirzepatide, a dual GIP and GLP-1 agonist, achieved up to 20.9% average weight loss at 15 mg weekly over 72 weeks in the SURMOUNT trials. Retatrutide's additional glucagon receptor activation drives further energy expenditure, which is believed to be the mechanism behind its superior weight loss outcomes compared to these dual-action predecessors.

From a dosing frequency perspective, all three medications share the convenience of once-weekly subcutaneous injection, making them broadly comparable in terms of administration burden. The key clinical differentiator is the magnitude of weight loss achievable at the highest doses. For the significant proportion of individuals with obesity who still do not achieve sufficient weight loss on semaglutide or tirzepatide, retatrutide represents a genuinely new therapeutic option once it clears regulatory review. In the meantime, approved weight loss injections remain the appropriate choice for those seeking treatment now.

  • Semaglutide (GLP-1 agonist): approximately 15% weight loss at 2.4 mg weekly
  • Tirzepatide (GLP-1 and GIP dual agonist): up to 20.9% weight loss at 15 mg weekly
  • Retatrutide (triple agonist): up to 24.2% weight loss at 12 mg weekly
  • All three share once-weekly subcutaneous injection administration
  • Retatrutide's glucagon receptor activity drives additional energy expenditure

Key Takeaways

  • Retatrutide is administered once weekly by subcutaneous injection, with Phase 2 trial doses ranging from 2 mg to 12 mg per week
  • The 12 mg weekly maintenance dose produced the greatest average weight loss of 24.2% over 48 weeks in clinical trials
  • Dosing always begins at a low starting dose (2 mg weekly) and escalates gradually over 16 to 24 weeks to minimise gastrointestinal side effects
  • Retatrutide is not currently approved by the MHRA and is not available as a prescribed medication in the UK as of 2026
  • For those seeking treatment now, clinically approved weekly injectables such as semaglutide and tirzepatide are available through regulated prescribers

When to Seek Professional Advice

If you are considering retatrutide or any other injectable weight loss medication, speaking with a qualified prescribing pharmacist or doctor is essential before making any decisions. Self-administering or sourcing unlicensed medications online carries serious health risks, including unknown product purity, incorrect dosing, and dangerous drug interactions. Only medications that have been approved by the MHRA and dispensed through a regulated pharmacy are safe and legally obtained.

You should seek professional advice urgently if you experience any of the following symptoms while on any GLP-1 class medication: severe and persistent abdominal pain radiating to the back (a potential sign of pancreatitis), signs of a severe allergic reaction, rapid heart rate, or significant worsening of any pre-existing conditions. These symptoms require immediate medical attention and you should not adjust or stop your dose without first consulting your prescriber.

For those with a BMI of 30 or above, or 27 or above with a weight-related health condition, speaking to a regulated prescriber about currently available approved weight loss injections is the appropriate first step. Our team at Cured Pharmacy includes qualified prescribing pharmacists who can guide you through what is clinically appropriate for your individual circumstances today, including all licensed options available in the UK.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Scientific References

  1. Jastreboff AM et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.
  2. National Institute for Health and Care Excellence (NICE). (2023). Semaglutide for managing overweight and obesity (TA875). NICE Technology Appraisal Guidance.
  3. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card Scheme: Guidance for Healthcare Professionals. GOV.UK.

Frequently Asked Questions

How long does it take for retatrutide to start working?

Retatrutide typically begins showing measurable weight reduction within four to eight weeks of starting treatment. Most participants in Phase 2 clinical trials reported noticeable appetite suppression within the first two weeks, with significant body weight changes becoming apparent after the first full titration phase was completed.

Is retatrutide safe to use long term?

Retatrutide's long-term safety profile is still being evaluated through ongoing Phase 3 clinical trials as of 2026. Early data from Phase 2 studies suggests a manageable side effect profile similar to other GLP-1 receptor agonists, but definitive long-term safety conclusions require the completion of current trials before regulatory bodies can assess them.

Can you take retatrutide with other weight loss medications?

Combining retatrutide with other weight loss medications is not currently recommended and has not been clinically studied in combination therapy. Taking multiple agents that affect appetite, blood sugar, or gastric emptying simultaneously carries significant risks and should only ever be considered under direct supervision from a qualified prescribing clinician.

What is the maximum dose of retatrutide per week?

The maximum dose of retatrutide studied in Phase 2 clinical trials was 12 mg administered once weekly by subcutaneous injection. This top dose was reached after a gradual titration schedule spanning approximately 24 weeks and produced the greatest average body weight reduction of approximately 24.2% in trial participants over 48 weeks.

Back to blog